GenTel BioSciences appoints Kendrick-Parker to board

Madison, Wis. - GenTel BioSciences, a protein chip-based life sciences company, has appointed Chris Kendrick-Parker to its Board of Directors.

Kendrick-Parker, who has Wisconsin ties, brings more than 20 years of experience in the life science industry to the GenTel board. Most recently, he spent nine years at Affymetrix, where he served as a vice president and managed all aspects of sales and marketing for the firm's Global Pharma Business Unit.

Alex Vodenlich, president and CEO of GenTel, said in a press release that Kendrick-Parker's industry experience will help ensure “that we are appropriately envisioning our future and setting the right performance goals.”

Prior to serving as vice president for Affymetrix, Kendrick-Parker was responsible for market development of the company's genetics business. He helped to establish key contacts and applications to grow its genome scanning market and chromosomal copy applications.

He also served as part of Amersham Pharmacia's drug discovery services team, and has 12 years of training in molecular and cellular biology in the Department of Human Oncology at the University of Wisconsin-Madison's Paul Carbone Comprehensive Cancer Center. Related stories

• GenTel Biosciences adds two South African scientists to Advisory Board

• GenTel acquires GlaxoSmithKline chip platform

• GenTel licenses next generation cancer research